|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hellmann MD, Li BT, Chaft JE and Kris MG:
Chemotherapy remains an essential element of personalized care for
persons with lung cancers. Ann Oncol. 27:1829–1835. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Danson S, Middleton MR, O'Byrne KJ,
Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C,
Stout R, et al: Phase III trial of gemcitabine and carboplatin
versus mitomycin, ifosfamide, and cisplatin or mitomycin,
vinblastine, and cisplatin in patients with advanced nonsmall cell
lung carcinoma. Cancer. 98:542–553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herbst RS, Baas P, Kim DW, Felip E,
Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui S, Su X, Dong L, Qian J, Ye L, Zhang
T, Fu H, Han H, Huang J, Yao Y, et al: Programmed cell death ligand
1 protein levels predicted survival of non-small cell lung cancer.
J Cancer. 8:4075–4082. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Azuma K, Ota K, Kawahara A, Hattori S,
Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et
al: Association of PD-L1 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann
Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin C, Chen X, Li M, Liu J, Qi X, Yang W,
Zhang H, Cai Z, Dai Y and Ouyang X: Programmed death-ligand 1
expression predicts tyrosine kinase inhibitor response and better
prognosis in a cohort of patients with epidermal growth factor
receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer.
16:e25–e35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu
Z and Huang JA: The EGFR pathway is involved in the regulation of
PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in
EGFR-mutated non-small cell lung cancer. Int J Oncol. 49:1360–1368.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin K, Cheng J, Yang T, Li Y and Zhu B:
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through
inhibiting NF-kappaB. Biochem Biophys Res Commun. 463:95–101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen N, Fang W, Zhan J, Hong S, Tang Y,
Kang S, Zhang Y, He X, Zhou T, Qin T, et al: Upregulation of PD-L1
by EGFR activation mediates the immune escape in EGFR-Driven NSCLC:
Implication for optional immune targeted therapy for NSCLC patients
with EGFR mutation. J Thorac Oncol. 10:910–923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, et al: Randomized, multinational, phase III study of
docetaxel plus platinum combinations versus vinorelbine plus
cisplatin for advanced non-small-cell lung cancer: The TAX 326
study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and function of the PD-L1 checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thunnissen E, de Langen AJ and Smit EF:
PD-L1 IHC in NSCLC with a global and methodological perspective.
Lung Cancer. 113:102–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramos-Vara JA and Miller MA: Comparison of
two polymer-based immunohistochemical detection systems: ENVISION+
and ImmPRESS. J Microsc. 224:135–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brody R, Zhang Y, Ballas M, Siddiqui MK,
Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in
advanced NSCLC: Insights into risk stratification and treatment
selection from a systematic literature review. Lung Cancer.
112:200–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shen X and Zhao B: Efficacy of PD-1 or
PD-L1 inhibitors and PD-L1 expression status in cancer:
Meta-analysis. BMJ. 362:k35292018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takada K, Okamoto T, Toyokawa G, Kozuma Y,
Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F,
et al: The expression of PD-L1 protein as a prognostic factor in
lung squamous cell carcinoma. Lung Cancer. 104:7–15. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y,
Wistuba II, Hirsch FR and IASLC Pathology Committee: Programmed
death-ligand 1 immunohistochemistry in lung cancer: In what state
is this art? J Thorac Oncol. 10:985–989. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang YL, Yang CY, Huang YL, Wu CT and
Yang PC: High PD-L1 expression is associated with stage IV disease
and poorer overall survival in 186 cases of small cell lung
cancers. Oncotarget. 8:18021–18030. 2017.PubMed/NCBI
|
|
29
|
Akamine T, Takada K, Toyokawa G, Kinoshita
F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa
T, et al: Association of preoperative serum CRP with PD-L1
expression in 508 patients with non-small cell lung cancer: A
comprehensive analysis of systemic inflammatory markers. Surg
Oncol. 27:88–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ikeda S, Okamoto T, Okano S, Umemoto Y,
Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y,
et al: PD-L1 is upregulated by simultaneous amplification of the
PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol.
11:62–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boussiotis VA: Molecular and biochemical
aspects of the PD-1 checkpoint pathway. N Engl J Med.
375:1767–1778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Horn L, Spigel DR, Vokes EE, Holgado E,
Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L,
et al: Nivolumab versus docetaxel in previously treated patients
with advanced non-small-cell lung cancer: Two-year outcomes from
two randomized, open-label, phase III trials (checkmate 017 and
checkmate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brahmer J, Reckamp KL, Baas P, Crino L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Miller VA, Riely GJ, Zakowski MF, Li AR,
Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, et
al: Molecular characteristics of bronchioloalveolar carcinoma and
adenocarcinoma, bronchioloalveolar carcinoma subtype, predict
response to erlotinib. J Clin Oncol. 26:1472–1478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Petrelli F, Maltese M, Tomasello G, Conti
B, Borgonovo K, Cabiddu M, Ghilardi M, Ghidini M, Passalacqua R,
Barni S and Brighenti M: Clinical and molecular predictors of PD-L1
expression in non-small-cell lung cancer. Systematic Clin Lung
Cancer. 19:315–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Martinez P, Peters S, Stammers T and Soria
JC: Immunotherapy for the first-line treatment of patients with
metastatic non-small cell lung cancer. Clin Cancer Res. 2019.
View Article : Google Scholar
|
|
42
|
Kerr KM and Nicolson MC: Non-small cell
lung cancer, PD-L1, and the pathologist. Arch Pathol Lab Med.
140:249–254. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kerr KM and Hirsch FR: Programmed death
ligand-1 immunohistochemistry: Friend or foe? Arch Pathol Lab Med.
140:326–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma
Y, Fang W, Yang Y, Hou X, Huang Y, et al: Immune-checkpoint
inhibitor plus chemotherapy versus conventional chemotherapy for
first-line treatment in advanced non-small cell lung carcinoma: A
systematic review and meta-analysis. J Immunother Cancer.
6:1552018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bethmann D, Feng Z and Fox BA:
Immunoprofiling as a predictor of patient's response to cancer
therapy-promises and challenges. Curr Opin Immunol. 45:60–72. 2017.
View Article : Google Scholar : PubMed/NCBI
|
